Business Wire

WA-SPIE

8.2.2024 22:02:36 CET | Business Wire | Press release

Share
With More Than 24,000 Registered, SPIE Photonics West 2024 Showcased a Robust and Expanding Industry

SPIE, the international society for optics and photonics, held an impactful and vibrant Photonics West last week at San Francisco’s Moscone Center, with 24,000-plus technical professionals registered from more than 70 countries across the international optics and photonics community. The largest annual photonics conference, which ran from 27 January to 1 February, hosted over 1,500 exhibitors, and featured over 5,000 technical presentations across an interactive and engaging week that included BiOS, LASE, OPTO, Quantum West, the BiOS Expo, the Photonics West exhibition, the Quantum West Expo, and the co-located AR|VR|MR conference and exhibition.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208158413/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SPIE Photonics West 2024 hosted an enthusiastic crowd of optics and photonics professionals at San Francisco's Moscone Center. (Photo: Business Wire)

“Photonics West heralds the beginning of the optics and photonics calendar each year for good reason,” said SPIE CEO Kent Rochford. “The invigorating energy and high levels of enthusiasm throughout the Moscone Center characterized a truly exciting week. AR|VR|MR continues to grow by leaps and bounds, and the addition of a standalone exhibit to the Quantum West program reflects the growing impact of the technology. We were also delighted by the success of our brand-new SPIE Global Business Forum, a packed event that drew top industry executives together for high-level presentations and conversation. Altogether it was a pleasure to be part of the networking, research-sharing, and collaborative discussions among world-leading scientists, engineers, students, and businesspeople and I’m already looking forward to Photonics West 2025.”

As always, the dynamic week showcased the latest innovative technologies and discoveries stemming from a diverse and thriving optics and photonics community, bringing together researchers, innovators, engineers, entrepreneurs, and business leaders from across the globe. Over 100 distinct technical conferences paired perfectly with the four exhibitions held during the week, bringing researchers and companies together to further science, technology, and applications. The week also included a wide range of live product demonstrations on the exhibition floors as well as a job fair.

The inaugural SPIE Global Business Forum was a resounding, sold-out success. With the 16th annual Prism Awards honoring the top new optics and photonics products, and the fast-paced Startup Challenge pitch competition, SPIE Photonics West recognized the best optics and photonics technologies, trends, and entrepreneurial opportunities, while the Quantum West Business Summit featured talks and panels that provided key insights into that expanding commercial ecosystem.

In addition, a program of 56 educational courses offered expert-led technical training and learning, which complemented the dozens of professional development and networking sessions. From Lunch and Learn programming focused on EDI, to networking and social events that provided many opportunities for in-person conversations and possible future collaborations, Photonics West featured a packed calendar of special events.

While the week held myriad opportunities for attendees to learn, network, and share their latest advancements, it was the buzzing exhibitions that best showcased the increasingly vital photonics industry and the importance of in-person meetings.

“The Global Business Forum made it clear that the optics and photonics industry is in the midst of a remarkable era of growth and innovation,” said Stratos Kehayas, PhD, Chief Product & Technology Officer, G&H. “The industry's collective enthusiasm at Photonics West underscores the pivotal role this trade show plays in driving collaboration, fostering innovation, and shaping the future.”

"This has been arguably one of the most productive Photonics Wests we've had in the last five years,” said nLIGHT Vice President and General Manager, Semiconductor Lasers, Matthew Randall. “It’s been very engaging, with lots of people coming through, and we're seeing new things at our booth and at other booths that make this particular show a positive experience. We are definitely seeing way more innovation now than in the last couple of years and that's been incredibly positive not only for nLIGHT, but for the entire photonics industry.”

“The week has been very good,” said MKS Instruments Senior Director of Marketing, Photonics Solutions Division, Vincent M. Issier. “The traffic has been very high and the attendance is incredible this year, and we are very happy with the level of engagement from people here.”

“The week has been great,” said IPG Photonics Director of Product Management, Beam Delivery, UV, Green & Ultrafast Lasers, Mustafa Coskun. “There was nice traffic coming through and it was really nice to connect with colleagues as well as our customers and other visitors. And this is what we're here for: to listen to our customers and understand what their problems are and how we can help them. This Photonics West has been great.”

“This year we were quite busy, even just walking around the show with so many people we know here and so many companies we are in touch with,” said TNO Business Consultant, Optics Manufacturing, Bart Snijders. “It’s great to see them all again. We’ve enjoyed being busy on the floor, busy with meetings. I would always like the show to be six or nine days long, because time is always too short for me here.”

During the Photonics West week, SPIE also announced its latest partnership – this one with The University of Manchester – in the SPIE Endowment Matching Program.

SPIE Photonics West 2025 will take place 25-30 January at the Moscone Center in San Francisco. The call for papers for the 2025 event will open in Spring of 2024.

About SPIE

SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $24 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240208158413/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye